Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock

Critical Care Medicine

Volumn 27, Issue 9, 1999, Pages 1701-1707

  Zingarelli, Basilia ^a   Haskó, György ^b,c   Salzman, Andrew L ^a,c   Szabó, Csaba ^a,b,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c INOTEK CORPORATION   (United States)

Author keywords

Contractility; Inflammation; Interferon; Lipopolysaccharide; Nitric oxide; Peroxynitrite; Raperfusion; Sepsis; Su rvival; Vascular

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; BACTERIUM LIPOPOLYSACCHARIDE; GUANYLATE CYCLASE INHIBITOR; NITRIC OXIDE; NORADRENALIN; PEROXYNITRITE;

ANTIOXIDANT ACTIVITY; AORTA MEDIA; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SEPSIS; SEPTIC SHOCK; SMOOTH MUSCLE FIBER; SURVIVAL; VASODILATATION;

ANIMALS; AORTA; CELL RESPIRATION; CELLS, CULTURED; ENZYME INHIBITORS; GUANYLATE CYCLASE; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; MALE; MICE; MITOCHONDRIA; MUSCLE, SMOOTH, VASCULAR; NITRATES; NITRIC OXIDE; NITRITES; OXADIAZOLES; OXIDANTS; QUINOXALINES; RATS; RATS, WISTAR; SHOCK, SEPTIC; SURVIVAL ANALYSIS; VASODILATION;

EID: 0032879115     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199909000-00001     Document Type: Review

References (61)

1. 1. Julou-Schaeffer G, Gray GA, Fleming I, et al: Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990; 259:H1038-H1043
2. 2. Rees DD, Cellek S, Palmer RMJ, et al: Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: An insight into endotoxin shock. Biochem Biophys Res Commun 1990; 173:541-546
3. 3. Kilbourn RG, Szabó C, Traber D: Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: Lessons learned from experimental and clinical studies. Shock 1997; 7:235-246
4. 4. Wu CC, Szabó C, Chen S, et al: Activation of soluble guanylyl cyclase by a factor other than nitric oxide or carbon monoxide contributes to the vascular hyporeactivity to vasoconstrictor agents in the aorta of rats treated with endotoxin. Biochem Biophys Res Commun 1994; 201:436-442
5. 5. Wu CC, Chen SJ, Szabó C, et al: Aminoguanidine inhibits the delayed circulatory failure in endotoxic and haemorrhagic shock in the anaesthetized rat. Br J Pharmacol 1995; 114: 1666-1672
6. 6. Szabó C, Southan GJ, Thiemermann C: Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a novel, potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 1994; 91: 2472-2476
7. 7. Szabó C, Bryk R, Zingarelli B, et al: Pharmacological characterization of guanidinoethyldisulphide (GED), a novel inhibitor of nitric oxide synthase with selectivity towards the inducible isoform. Br J Pharmacol 1996; 118:1659-1668
8. 8. Fishman D, Liaudet L, Lazor R, et al: L-Canavanine, an inhibitor of inducible nitric oxide synthase, improves venous return in endotoxemic rats. Crit Care Med 1997; 25: 469-475
9. 9. Southan GJ, Szabó C: Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996; 51:383-394
10. 2+ by sarcoplasmic reticulum in vascular smooth muscle. Circ Res 1988; 62: 962-964
11. 11. Ignarro LJ: Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 1991; 41:485-490
12. 12. Schmidt HHHW, Lohmann SM, Walter U: The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action. Biochem Biophys Acta 1993; 1178: 153-175
13. 13. Schneider F, Lutun P, Hasselmann M, et al: Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations. Intensive Care Med 1992; 18:309-311
14. 14. Paya D, Gray GA, Stoclet JC: Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats. J Cardiovasc Pharmacol 1993; 21:926-930
15. 15. Preiser JC, Lejeune P, Roman A, et al: Methylene blue administration in septic shock: A clinical trial. Crit Care Med 1995; 23: 259-264
16. 16. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, et al: Methylene blue increases myocardial function in septic shock. Crit Care Med 1995; 23:1363-1370
17. 17. Gachot B, Bedos JP, Veber B, et al: Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med 1995; 21: 1027-1031
18. 18. Keaney JF Jr, Puyana JC, Francis S, et al: Methylene blue reverses endotoxin-induced hypotension. Circ Res 1994; 74:1121-1125
19. 19. Zhang H, Rogiers P, Preiser JC, et al: Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock. Crit Care Med 1995; 23:1711-1721
20. 20. Mayer B. Brunner F. Schmidt K: Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993; 45:367-374
21. 21. Shimizu S. Yamamoto T. Momose K: Inhibition by methylene blue of the L-arginine metabolism to L-citrulline coupled with nitric oxide synthesis in cultured endothelial cells. Res Commun Chem Pathol Pharmacol 1993; 82:35-48
22. 22. Luo D, Das S, Vincent SR: Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase. Eur J Pharmacol 1995; 290:247-251
23. 23. Stockand JD, Sansom SC: Activation by methylene blue of large Ca(2+)-activated K+ channels. Biochim Biophys Acta 1996; 1285:123-126
24. 24. Pfaffendorf M, Bruning TA, Batnik HD, et al: The interaction between methylene blue and the cholinergic system. Br J Pharmacol 1997; 122:95-98
25. 25. Abi-Gerges N, Eschenhagen T, Hove-Madsen L, et al: Methylene blue is a muscarinic antagonist in cardiac myocytes. Mol Pharmacol 1997; 52:482-490
26. 26. Visarius TM, Stucki JW, Lauterburg BH: Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett 1997; 412:157-160
27. 27. Beckman JS, Beckman TW, Chen J, et al: Apparent hydroxyl radical production by peroxynitrite: Implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990; 87:1620-1624
28. 28. Szabó C: The role of peroxynitrite in the pathophysiology of shock, inflammation and ischemia-reperfusion injury. Shock 1996; 6:79-88
29. 29. Wu CC, Chen SJ, Yen MH: Different responses to acetylcholine in the presence of nitric oxide inhibitor in rat aortae and mesenteric arteries. Clin Exp Pharmacol Physiol 1993; 20:405-412
30. 30. Bolotina VM, Najibi S, Palacino JJ, et al: Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994; 368:850-853
31. 31. Hohn J, Pataricza J, Toth GK, et al: Nitric oxide activates an iberiotoxin-sensitive potassium channel in human saphenous vein. Acta Physiol Hung 1996; 84:293-294
32. 32. Wei EP, Kontos HA, Beckman JS: Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am J Physiol 1996; 271:H1262-H1266
33. 33. Onoue H, Katusic ZS: Role of potassium channels in relaxations of canine middle cerebral arteries induced by nitric oxide donors. Stroke 1997; 28:1264-1270
34. 34. Szabó C, Zingarelli B, Salzman AL: Role of poly-ADP ribosyltransferase activation in the nitric oxide- and peroxynitrite-induced vascular failure. Circ Res 1996; 78:1051-1063
35. 2+-ATPase by peroxynitrite. Free Radical Res 1996; 24:243-259
36. 36. Salvemini D: Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci 1997; 53:576-582
37. 37. Landino LM, Crews BC, Timmons MD, et al: Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci U S A 1996; 93:15069-15074
38. 38. Schrammel A, Behrends S, Schmidt K, et al: Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996; 50:1-5
39. 39. Garthwaite J, Southam E, Boulton CL, et al: Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 1995; 48:184-188
40. 40. Brunner F, Schmidt K, Nielsen EB, et al: Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. J Pharmacol Exp Ther 1996; 277: 48-53
41. 41. Moro MA, Russel RJ, Cellek S, et al: cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A 1996; 93:1480-1485
42. 42. Olson LJ, Knych ET Jr, Herzig TC, et al: Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation. Hypertension 1997; 29:254-261
43. 43. Nakayama I, Kawahara Y, Tsuda T, et al: Cyclic AMP elevating agents synergize with inflammatory cytokines to induce an inducible type of nitric oxide synthase in cultured-vascular smooth muscle cells. Ann NY Acad Sci 1995; 748:586-589
44. 44. Inoue T, Fukuo K, Nakahashi T, et al: cGMP upregulates nitric oxide synthase expression in vascular smooth muscle cells. Hypertension 1995; 25:711-714
45. 45. Pahan K, Namboodiri AM, Sheikh FG, et al: Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J Biol Chem 1997; 272: 7786-7791
46. 46. Polte T, Oberle S, Schroder H: Nitric oxide protects endothelial cells from tumor necrosis factor-alpha-mediated cytotoxicity: Possible involvement of cyclic GMP. FEBS Lett 1997; 409:46-48
47. 47. Geng YJ, Wu Q, Hansson GK: Protein kinase C activation inhibits cytokine-induced nitric oxide synthesis in vascular smooth muscle cells. Biochim Biophys Acta 1994; 1223: 125-132
48. 48. Szabó C, Thiemermann C, Wu CC, et al: Inhibition of nitric oxide synthase induction by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci U S A 1994; 91:271-275
49. 49. Christodoulides N, Durante W, Kroll MH, et al: Vascular smooth muscle cell heme oxygenases generate guanylyl cyclase-stimulatory carbon monoxide. Circulation 1995; 91: 2306-2309
50. 50. Driscoll W, Thurin S, Carrion V, et al: Effect of methylene blue on refractory neonatal hypotension. J Pediatrics 1996; 129:904-908
51. 51. Schreiber MD: Methylene blue: NO panacea. J Pediatr 1996; 129:790-793
52. 52. Marczin N, Tekeres M, Salzman AL, et al: Methylene blue infusion in septic shock. Crit Care Med 1996; 23:1936-1938
53. 53. Marczin N, Ryan US, Catravas JD: Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. J Pharmacol Exp Ther 1992; 263:170-179
54. 54. Kontos HA, Wei EP: Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke 1993; 24:427-434
55. 55. Brady AJ, Poole-Wilson PA, Harding SE, et al: Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992; 263:H1963-H1966
56. 56. Schneider F: Methylene blue infusion in septic shock. Crit Care Med 1995; 23:1935-1936
57. 57. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6:3051-3064
58. 58. Green SJ, Nacy G: Antimicrobial and immunopathologic effects of cytokine-induced nitric oxide synthesis. Curr Opin Infect Dis 1993; 6:384-390
59. 59. Fouty B, Komalavilas P, Muramatsu M, et al: Protein kinase G is not essential to NO-cGMP modulation of basal tone in rat pulmonary circulation. Am J Physiol 1998; 274: H672-H678
60. 60. Kojda G, Kottenberg K, Noack E: Inhibition of nitric oxide synthase and soluble guanylate cyclase induces cardiodepressive effects in normal rat hearts. Eur J Pharmacol 1997; 334:181-190
61. 61. Chetham PM, Sefton WD, Bridges JP, et al: Inhaled nitric oxide pretreatment but not post-treatment attenuates ischemia-reperfusion-induced pulmonary microvascular leak. Anesthesiology 1997; 86:895-902